پایان نامه ارشد درباره VEGF، growth، endothelial، H,

. 2005;26(1):33-65.
14. Li WW, Tsakayannis D, Li VW. Angiogenesis: a control point for normal and delayed wound healing. Contemp Surg. 2003;1:5-11.
15. Guo C, Henley JM. Wrestling with stress: roles of protein SUMOylation and deSUMOylation in cell stress response. IUBMB life. 2014;66(2):71-7.
16. Nemet D, Oh Y, Kim H-S, Hill M, Cooper DM. Effect of intense exercise on inflammatory cytokines and growth mediators in adolescent boys. Pediatrics. 2002;110(4):681-9.
17. Yeh ET. SUMOylation and De-SUMOylation: wrestling with life’s processes. Journal of Biological Chemistry. 2009;284(13):8223-7.
18. Ahmetov I, Khakimullina A, Popov D, Missina S, Vinogradova O, Rogozkin V. Polymorphism of the vascular endothelial growth factor gene (VEGF) and aerobic performance in athletes. Human Physiology. 2008;34(4):477-81.
19. Roy S, Khanna S, Sen CK. Redox regulation of the VEGF signaling path and tissue vascularization: Hydrogen peroxide, the common link between physical exercise and cutaneous wound healing. Free Radical Biology and Medicine. 2008;44(2):180-92.
20. Suzuki J. L-Arginine and L-Ornithine Supplementation Facilitates Angiogenesis and Causes Additional Effects on Exercise-induced Angiogenesis in Hind-leg Muscles. Advances in exercise and sports physiology. 2009;15(3):101-8.
21. Nourshahi M, chadorneshin HT, Ranjbar K. The stimulus of angiogenesis during exercise and physical
activity. Quarterly of the Horizon of Medical Sciences. 2013;18(5):286-96.
22. Mansoor JK, Morrissey BM, Walby WF, Yoneda KY, Juarez M, Kajekar R, et al. L-arginine supplementation enhances exhaled NO, breath condensate VEGF, and headache at 4342 m. High altitude medicine & biology. 2005;6(4):289-300.
23. Shibuya M. Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. BMB Reports. 2006;39(5):469-78.
24. Nowroozzadeh MH, Sharifi M. Anti-vascular endothelial growth factor (Anti-VEGF) as a potential novel adjunct in the management of choroidal melanoma. Journal of Medical Hypotheses and Ideas (Formerly: Iranian Journal of Medical Hypotheses and Ideas). 2008;2.
25. Adams MR, McCredie R, Jessup W, Robinson J, Sullivan D, Celermajer DS. Oral L-arginine improves endothelium-dependent dilatation and reduces monocyte adhesion to endothelial cells in young men with coronary artery disease. Atherosclerosis. 1997;129(2):261-9.
26. Prior BM, Yang H, Terjung RL. What makes vessels grow with exercise training? Journal of Applied Physiology. 2004;97(3):1119-28.
27. Gustafsson T, Ameln H, Fischer H, Sundberg C, Timmons J, Jansson E. VEGF-A splice variants and related receptor expression in human skeletal muscle following submaximal exercise. Journal of Applied Physiology. 2005;98(6):2137-46.
28. Goumas G, Tentolouris C, Tousoulis D, Stefanadis C, Toutouzas P. Therapeutic modification of the L-arginine-eNOS pathway in cardiovascular diseases. Atherosclerosis. 2001;154(2):255-67.
29. McConell GK. Effects of L-arginine supplementation on exercise metabolism. Current Opinion in Clinical Nutrition & Metabolic Care. 2007;10(1):46-51.
30. Suzuki J. Influence of amino acid supplementation on capillary growth in the heart and skeletal muscles. The Journal of Physical Fitness and Sports Medicine. 2013;2(2):237-41.
31. ?lvares T, Meirelles C, Bhambhani Y, Paschoalin VF, Gomes PC. L-Arginine as a Potential Ergogenic Aidin Healthy Subjects. Sports Med. 2011;41(3):233-48.
32. Fiorito C, Balestrieri ML, Crimi E, Giovane A, Grimaldi V, Minucci PB, et al. Effect of l-arginine on circulating endothelial progenitor cells and VEGF after moderate physical training in mice. International journal of cardiology. 2008;126(3):421-3.
33. Suzuki J. L-arginine supplementation causes additional effects on exercise-induced angiogenesis and VEGF expression in the heart and hind-leg muscles of middle-aged rats. J Physiol Sci. 2006;56(1):39-44.
34. Lerman A, Burnett JC, Higano ST, McKinley LJ, Holmes DR. Long-term L-arginine supplementation improves small-vessel coronary endothelial function in humans. Circulation. 1998;97(21):2123-8.
35. Prior BM, Lloyd PG, Yang H, Terjung RL. Exercise-induced vascular remodeling. Exercise and sport sciences reviews. 2003;31(1):26-33.
36. Prior SJ. DNA Sequence Variation in the Promoter Region of the VEGF Gene: Impacts on VEGF Gene Expression and Maximal Oxygen Consumption. 2005.
37. Folkman J. Angiogenesis. Annual review of medicine. 2006;57:1-18.
38. Sia D, Alsinet C, Newell P, Villanueva A. VEGF Signaling in Cancer Treatment. Current Pharmaceutical Design. 2014;20(17):2834-42.
39. Beam W, Adams G. Exercise physiology laboratory manual: McGraw-Hill Higher Education; 2013.
40. Campbell BI, La Bounty PM, Roberts M. The ergogenic potential of arginine. J Int Soc Sports Nutr. 2004;1(2):35-8.
41. Breier G. Angiogenesis in Embryonic Development-A Review. Placenta. 2000;21:S11-S5.
42. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature medicine. 1995;1(1):27-30.
43. Lloyd PG, Prior BM, Li H, Yang HT, Terjung RL. VEGF receptor antagonism blocks arteriogenesis, but only partially inhibits angiogenesis, in skeletal muscle of exercise-trained rats. American Journal of Physiology-Heart and Circulatory Physiology. 2005;288(2):H759-H68.
44. http://www.rndsystems.com/Pathway.aspx?p=18690&r=15436.
45. Chung HJ, Mahalingam M. Angiogenesis, vasculogenic mimicry and vascular invasion in cutaneous malignant melanoma – implications for therapeutic strategies and targeted therapies. Expert Review of Anticancer Therapy. 2014;14(5):621-39.
46. Mart?nez A. A new family of angiogenic factors. Cancer letters. 2006;236(2):157-63.
47. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. The FASEB Journal. 1999;13(1):9-22.
48. Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT, De Bruijn EA. Vascular endothelial growth factor and angiogenesis. Pharmacological reviews. 2004;56(4):549-80.
49. Hauk JM, Hosey RG. Nitric oxide therapy: fact or fiction? Current sports medicine reports. 2006;5(4):199.
50. B?ger RH, Ron ES. L-Arginine Improves Vascular Function by Overcoming the Deleterious Effects of ADMA, a Novel Cardiovascular Risk Factor. Alternative medicine review. 2005;10(1).
51. El Assar De La Fuente M, Angulo Frutos J, Vallejo Fern?n S, Peir? Vallejo C, S?nchez-Ferrer CF, Rodr?guez-Ma?as L. Mechanisms involved in the aging-induced vascular dysfunction. Frontiers in Physiology. 2012;3.
52. Tsai P-H, Tang T-K, Juang C-L, Chen K, Chi C-A, Hsu M-C. Effects of arginine supplementation on post-exercise metabolic responses. Chin J Physiol. 2009;52(3):136-42.
53. Alderton W, Cooper C, Knowles R. Nitric oxide synthases: structure, function and inhibition. Biochem J. 2001;357:593-615.
54. Bilusic M, Wong YN. Anti-angiogenesis in prostate cancer: knocked down but not out. Asian Journal of Andrology. 2014;16(3):372-7.
55. http://www.pdb.org/pdb/explore/explore.do?structureId=1KOE.
56. Heljasvaara R, Nyberg P, Luostarinen J, Parikka M, Heikkil? P, Rehn M, et al. Generation of biologically active endostatin fragments from human collagen XVIII by distinct matrix metalloproteases. Experimental cell research. 2005;307(2):292-304.
57. Sauter BV, Martinet O, Zhang W-J, Mandeli J, Woo SL. Adenovirus-mediated gene transfer of endostatin in vivo results in high level of transgene expression and inhibition of tumor growth and metastases. Proceedings of the National Academy of Sciences. 2000;97(9):4802-7.
58. Joki T, Machluf M, Atala A, Zhu J, Seyfried NT, Dunn IF, et al. Continuous release of endostatin from microencapsulated engineered cells for tumor therapy. Nature biotechnology. 2001;19(1):35-9.
59. Blezinger P, Wang J, Gondo M, Quezada A, Mehrens D, French M, et al. Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene. Nature biotechnology. 1999;17(4):343-8.
60. Sasaki T
, Fukai N, Mann K, G?hring W, Olsen BR, Timpl R. Structure, function and tissue forms of the C?terminal globular domain of collagen XVIII containing the angiogenesis inhibitor endostatin. The EMBO Journal. 1998;17(15):4249-56.
61. Digtyar A, Pozdnyakova N, Feldman N, Lutsenko S, Severin S. Endostatin: current concepts about its biological role and mechanisms of action. Biochemistry (Moscow). 2007;72(3):235-46.
62. Cao Y, Cao R, Veitonmaki N. Kringle structures and antiangiogenesis. Current Medicinal Chemistry-Anti-Cancer Agents. 2002;2(6):667-81.
63. Pestell RG, Li Z. Antisense to cyclin D1 inhibits VEGF-stimulated growth of vascular endothelial cells: implication of tumor vascularization. Clinical Cancer Research. 2006;12(15):4459-62.
64. Wernicke AG, Varma S, Greenwood EA, Christos PJ, Chao KSC, Liu H, et al. Prostate-specific membrane antigen expression in tumor-associated vasculature of breast cancers. Apmis. 2014;122(6):482-9.
65. Olsson A-K, Johansson I, ?kerud H, Einarsson B, Christofferson R, Sasaki T, et al. The minimal active domain of endostatin is a heparin-binding motif that mediates inhibition of tumor vascularization. Cancer research. 2004;64(24):9012-7.
66. Mott JD, Werb Z. Regulation of matrix biology by matrix metalloproteinases. Current opinion in cell biology. 2004;16(5):558-64.
67. Awata T, Inoue K, Kurihara S, Ohkubo T, Watanabe M, Inukai K, et al. A common polymorphism in the 5?-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. Diabetes. 2002;51(5):1635-9.
68. Howell W, Ali S, Rose-Zerilli M, Ye S. VEGF polymorphisms and severity of atherosclerosis. Journal of medical genetics. 2005;42(6):485-90.
69. Greenberger S, Boscolo E, Adini I, Mulliken JB, Bischoff J. Corticosteroid suppression of VEGF-A in infantile hemangioma-derived stem cells. New England Journal of Medicine. 2010;362(11):1005-13.
70. Simonetti O, Lucarini G, Goteri G, Zizzi A, Biagini G, Lo ML, et al. VEGF is likely a key factor in the link between inflammation and angiogenesis in psoriasis: results of an immunohistochemical study. International journal of immunopathology and pharmacology. 2005;19(4):751-60.
71. Paleolog EM, Young S, Stark AC, McCloskey RV, Feldmann M, Maini RN. Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor ? and interleukin?1 in rheumatoid arthritis. Arthritis & Rheumatism. 1998;41(7):1258-65.
72. Gealekman O, Burkart A, Nicoloro SM, Straubhaar J, Corvera S. Enhanced angiogenesis in obesity and in response to PPAR? activators through adipocyte VEGF and ANGPTL4 production. American Journal of Physiology-Endocrinology and Metabolism. 2008;295(5):E1056-E64.
73. Hoier B, Hellsten Y. Exercise?Induced Capillary Growth in Human Skeletal Muscle and the Dynamics of VEGF. Microcirculation. 2014;21(4):301-14.
74. Breen E, Tang K, Olfert M, Knapp A, Wagner P. Skeletal muscle capillarity during hypoxia: VEGF and its activation. High Altitude Medicine & Biology. 2008;9(2):158-66.
75. Laughlin M, Roseguini B. Mechanisms for exercise training-induced increases in skeletal muscle blood flow capacity: differences with interval sprint training versus aerobic endurance training. Journal of physiology and pharmacology: an official journal of the Polish Physiological Society. 2008;59(Suppl 7):71.
76. Richardson R, Wagner H, Mudaliar S, Henry R, Noyszewski E, Wagner P. Human VEGF gene expression in skeletal muscle: effect of acute normoxic and hypoxic exercise. American Journal of Physiology-Heart and Circulatory Physiology. 1999;277(6):H2247-H52.
77. Paniagua OA, Bryant MB, Panza JA. Role of Endothelial Nitric Oxide in Shear Stress-Induced Vasodilation of Human Microvasculature Diminished Activity in Hypertensive and Hypercholesterolemic Patients. Circulation. 2001;103(13):1752-8.
78. Dellamea BS, Leit?o CB, Friedman R, Canani LH. Nitric oxide system and diabetic nephropathy. Diabetology & metabolic syndrome. 2014;6(1):17.
79. Corbett EJ. Effects of Oral L-arginine

دیدگاهتان را بنویسید